Abstract
Introduction
The obesity market is easily characterized as attractive, featuring a booming
patient potential needing long term therapy, but repeated product withdrawals
and failed pipeline candidates highlight the reality of increasingly cautious
regulatory bodies, reluctant payers, and a clinical community that puts more
stock in diet and exercise: $513.7m sales in 2008 fall far short of analyst
predictions.
Key reasons to purchase this research
- Understand why predictions for this market have been repeatedly over-stated
- Qualify market expectations against the practicalities of targeting this
unyielding market
- Assess the qualities of marketed and pipeline products and their
commercial handling to determine their realistic prospects
| 
View Cart
